NACLC 2022 | Differences in treating lung cancer with adjuvant and neoadjuvant immunotherapy

Ryan Gentzler, MD, University of Virginia, Charlottesville, VA, provides a comparison of adjuvant and neoadjuvant immunotherapy in patients with lung cancer. Multiple studies including the CheckMate 816 (NCT02998528), IMpower010 (NCT02486718), and KEYNOTE-091 (NCT02504372) trials, which assessed nivolumab plus ipilimumab, atezolizumab, and pembrolizumab respectively, have assessed these checkpoint inhibitors in the perioperative setting. Whilst there are differences in patient selection for adjuvant and neoadjuvant immunotherapy, the neoadjuvant therapy may be more beneficial due to the increased presence of tumors in patients receiving neoadjuvant treatment. This interview took place at the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.